Clinical

Experts at AMCP 2026 outlined volatility across the health care landscape that may impact the upcoming midterm elections.

Community response teams can adapt hospital rapid response principles for managed care organizations, targeting rising-risk members to prevent costly clinical deterioration and generate measurable cost savings.

Two posters presented at AMCP 2026 found low dry eye disease (DED) treatment uptake and frequent discontinuation among Medicare patients, whereas comorbid DED did not affect glaucoma adherence.

A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.

Two posters presented at AMCP 2026 suggest improving GLP-1 adherence and access may enhance outcomes and lower obesity-related costs.

Psychological effects of alopecia areata should be looked into in the future for patients who live with the condition.

Housing and transportation barriers were linked to lower CRC screening rates, especially among adults aged 50 to 64.

Finerenone lowered cardiovascular death and HF events irrespective of coronary heart disease status but did not reduce atherothrombotic outcomes.

Two AAD 2026 posters highlight persistent melanoma disparities: men have worse survival, whereas minority patients are less likely to receive home or hospice end-of-life care.

At-home phototherapy is more convenient than in-office care, and investigators found its one-time costs are also far less than the cost of care in a clinic.

Steven Daveluy, MD, discusses 3-year findings that show 86% of patients remained HS flare-free throughout treatment, reinforcing the case for early intervention.

A real-world study has found that personalizing ibrutinib doses based on patient health does not compromise survival outcomes in chronic lymphocytic leukemia (CLL).

Both Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores improved after treatment.

Phase 3 CANOPY data show pemivibart safely prevented COVID-19 in patients with CLL, supporting EUA use for immunocompromised populations.

Poor outcomes could be predicted based on the presence of ectopic germinal centers in the thymus in patients with thymoma-associated myasthenia gravis.

Sequential therapy of ranibizumab and a dexamethasone implant improved results in macular edema secondary to non–ischemic retinal vein occlusion.

JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long COVID risk and symptom severity.

Ajai Chari, MD, discusses the teclistamab-daratumumab approval, highlighting durable remissions, infection management, and the need for community oncologist uptake.

Benjamin Lockshin, MD, FAAD, examines how geographic variation in psoriasis patient characteristics and biologic prescribing reflects a complex interplay of insurance access, formulary structure, practice site demographics, and regional socioeconomic factors.

Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient counseling, and versatility in managing psoriatic comorbidities.

Two-year data confirm DOR/ISL delivers durable viral suppression—even in patients with high viral loads or advanced disease.

A study suggests vitamin D may reduce long COVID symptoms at 8 weeks, although larger trials are needed to confirm benefits and optimal timing, explains JoAnn E. Manson, MD, MPH, DrPH.

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can improve outcomes for people with MS.

Proactive adverse effect management helps patients with skin cancer stay on treatment longer, according to Todd Schlesinger, MD.

Zanubrutinib had low discontinuation and atrial fibrillation rates in R/R CLL/SLL, supporting tolerability over first-generation BTK inhibitors.